Alle Studien
RekrutierungBEOBACHTEND

The European Paediatric Network for Haemophilia Management ( PedNet Registry)

The PedNet Registry is an international study focusing on children born with haemophilia A or B. Because haemophilia is a rare condition, doctors collaborate across many hospitals to gather enough information. The main goal is to learn more about bleeding episodes in babies, understand why some children develop 'inhibitors' (which can make treatment harder), and see how children with haemophilia fare over time. The study simply collects details about the child's usual medical care from their records, without adding extra appointments or tests. This helps researchers improve future care and guidance for all children with haemophilia, even though individual participants won't notice a direct change in their health.

Auf einen Blick

Status
Rekrutierung
Sponsor
PedNet Haemophilia Research Foundation
Einschreibeziel
4,000
Starten
01 Jun 2014
Geschätzte Fertigstellung
01 Dec 2039

Worum geht es in dieser Studie?

Haemophilia is a rare condition where blood doesn’t clot properly, leading to bleeding problems. Because it's so uncommon, it's hard for one hospital alone to gather enough information to understand it fully. This is why the PedNet Registry was created – it’s a big study involving many hospitals across Europe. The main idea is to collect health information from lots of children with haemophilia A or B, all born between 2000 and 2040.

The study wants to learn several key things. For example, it looks at bleeding in newborn babies, and tries to understand why some children develop 'inhibitors.' Inhibitors are like antibodies that can make the usual haemophilia treatment less effective. The study also tracks the long-term health of these children, particularly how their joints are affected over time. By looking at a large group of children, researchers hope to find patterns and factors that influence these important aspects of haemophilia.

It's important to know that this is an 'observational' study. This means your child will not receive any new treatments or interventions specifically for this study. Instead, doctors will simply record information from your child's regular medical care, including details about their diagnosis, treatments, and any bleeding episodes. This information is usually collected anyway as part of their routine check-ups. The aim is to use this de-identified data to create better guidelines and improve care for all children with haemophilia in the future.

Wichtige Erkenntnisse

  • It's a study for children with haemophilia A or B.
  • No new treatments or extra appointments are involved.
  • Doctors will use information from your child’s routine medical records.
  • The study aims to understand bleeding, 'inhibitors', and long-term health in children with haemophilia.
  • It helps develop better care and guidelines for all children with haemophilia.
  • Your child will not have any direct individual health benefits from participating.

Wer könnte berechtigt sein?

To be part of this study, a child would generally need to have been diagnosed with haemophilia A or B. Their Factor VIII or IX levels (which measure how well their blood clots) should be between less than 1% and 25%.

They also need to have detailed medical records about their haemophilia treatment and any bleeding episodes. Finally, the child must be receiving care at one of the hospitals participating in this study.

A child cannot join if they were referred to a hospital specifically because they already have an 'inhibitor' (a complication that can make treatment harder), or if the parents/guardians do not give their permission.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. Does your child have haemophilia A or B?
  2. Are their Factor VIII/IX levels between less than 1% and 25%?
  3. Are their medical records for treatment and bleeds complete?
  4. Is your child currently treated at a hospital taking part in this study?
  5. Was your child *not* referred to this hospital specifically because they already have an inhibitor?
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If your child takes part in this study, you won't notice any changes to their medical care. There are no extra hospital visits, tests, or medication involved. The doctors and nurses will simply gather information from your child's existing medical records and from their routine check-ups. This includes details like their Factor VIII or IX levels, family history, genetic information, treatment records, and how their joints are doing. They will also record any bleeding episodes. All the information collected is part of the standard care your child would receive anyway, so it doesn't add any extra burden. The study will continue for many years, following children born between 2000 and 2040, but your child's individual participation simply involves allowing their routine medical data to be used.

Potenzielle Risiken und Vorteile

There are no direct risks to your child from taking part in this study because it only involves collecting information from their medical records, not giving new treatments or extra tests. There are also no direct benefits to your child's health that you would notice immediately. However, collaborating with many hospitals to study a rare condition like haemophilia helps doctors learn more, ultimately leading to better future care and guidelines for all children with haemophilia. This study is crucial for understanding how the condition affects young children. You are always free to decide to withdraw your child's data from the study at any time without it affecting their medical care.

Locations (39)

  • Universitäts-Klinik für Kinder- und Jugendheilkunde
    Verifizierte Postleitzahl
    Graz, Österreich· Abgeschlossen
  • Medical University of Vienna - Department of Paediatrics
    Verifizierte Postleitzahl
    Wien, Österreich· Rekrutierung
  • Service of Pediatric Haematology University Hospital Leuven
    Verifizierte Postleitzahl
    Leuven, Belgien· Rekrutierung
  • Division of Hematology/Oncology Hôpital St Justine
    Verifizierte Postleitzahl
    Montreal, Kanada· Rekrutierung
  • Division of Haematology/Oncology Hospital for Sick Children
    Verifizierte Postleitzahl
    Toronto, Kanada· Rekrutierung
  • Haemophilia Comprehensive Care Centre, Centre for Thrombosis and Haemostasis Children's University Hospital Brno
    Verifizierte Postleitzahl
    Brünn, Tschechien· Rekrutierung
  • Department of Paediatric Haematology/oncology - University Hospital Motol
    Verifizierte Postleitzahl
    Prag, Tschechien· Rekrutierung
  • Department of Pediatrics Århus Kommunehospital Skejby Sygehus
    Verifizierte Postleitzahl
    Aarhus, Denmark· Rekrutierung
  • Children's Hospital Helsinki University Hospital
    Verifizierte Postleitzahl
    Helsinki, Finnland· Rekrutierung
  • Service Hématologique Centre Regional Traitement d'Hemophilie Bicetre
    Verifizierte Postleitzahl
    Le Kremlin-Bicêtre, France· Rekrutierung
  • Service d'Hématologie Pédiatrique Hôpital Universitaire La Timone
    Unbestätigt
    Marseille Cedex-05, France· Rekrutierung
  • Centre de traitement des hémophiles Hôpital Universitaire Purpan
    Verifizierte Postleitzahl
    Toulouse, Frankreich· Rekrutierung

Häufige Fragen

What is haemophilia?

Haemophilia is a rare inherited condition where blood doesn't clot properly, which can lead to longer bleeding after an injury or surgery.

What is an 'inhibitor'?

An 'inhibitor' is when the body creates antibodies against the treatment for haemophilia, making the treatment less effective.

Will my child get new medicines for this study?

No, your child will not receive any new medicines or treatments specifically for this study. Doctors will only record details of their usual care.

Will we have extra hospital visits?

No, taking part in this study will not mean any extra visits to the hospital. All information is collected during your child's routine appointments.

How will this study help?

By collecting information from many children, doctors hope to understand haemophilia better, which can lead to improved treatments and guidelines for all children with the condition in the future.

Wie Sie mehr erfahren können

Angelique Hermeling

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Interessiert daran, teilzunehmen?

Registrieren Sie Ihr Interesse

Teilen Sie Ihre Details und das Forschungsteam für "The European Paediatric Network for Haemophilia Management (… wird Sie kontaktieren, wenn Sie möglicherweise infrage kommen. Sprechen Sie immer mit Ihrem Hausarzt, bevor Sie zustimmen, teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.